Key Highlights

  • Barzolvolimab missed the primary endpoint of at least a four-point WI-NRS itch improvement at week 12 in a 140-patient Phase 2 prurigo nodularis trial, and missed key secondary endpoints, despite confirmed systemic mast cell depletion; Celldex has discontinued the indication.
  • The share-price impact was modest: as much as 10% after hours on 21 July, a 2.5% close-to-close decline on 22 July, and full recovery within two sessions.
  • The thesis rests on Phase 3 EMBARQ-CSU1 and CSU2 in chronic spontaneous urticaria, enrolling 1,939 patients, with topline data guided for September or October 2026 and a BLA planned for 2027.
  • EMBARQ-CSU1 and CSU2 topline data, guided by the company for September or October 2026.

Celldex (NASDAQ:CLDX) said on 21 July 2026 that barzolvolimab failed to beat placebo on itch in a 140-patient Phase 2 trial in prurigo nodularis, and that it is abandoning the indication. Shares dropped as much as 10% after hours but closed the next session down only 2.5%, recovering within two days. The muted reaction says more about what investors are actually waiting for: pivotal chronic urticaria data due within weeks.

The press release landed after the closing bell on Tuesday 21 July. Barzolvolimab, Celldex Therapeutics' anti-KIT antibody and effectively the company's whole equity story, had not helped patients with prurigo nodularis. Not at 150 mg. Not at 300 mg. Not at week 12, and not at week 24. Celldex is discontinuing the study and the indication.

What followed was more interesting than the failure. Shares fell as much as 10% in after-hours trading, traded down roughly 7% before the open, then spent the day clawing most of it back, closing at $34.77 against $35.66 the day before. By Thursday the stock was at $35.42, above where it started. A failure that erased an entire addressable market moved the market capitalisation by less than 3% for one session. That gap between the scientific setback and the share-price shrug is the thing worth understanding.

What Happened

The discontinued trial was a randomised, double-blind, placebo-controlled Phase 2 study run across 48 centres in six countries, enrolling 140 patients with moderate-to-severe prurigo nodularis who had not responded to prescription topical treatment. Patients received barzolvolimab at 150 mg or 300 mg every four weeks after a 450 mg loading dose, or placebo, for 24 weeks, followed by a 16-week observation period.

The primary endpoint was the proportion of patients achieving at least a four-point improvement on the Worst Itch Numeric Rating Scale at week 12. According to the company's announcement, neither dose separated from placebo on that measure, nor on the key secondary endpoint of clear or almost-clear skin on the investigator's lesion scale. There was no improvement at week 24 either. Celldex did not publish response percentages or p-values in the release.

The drug did what it was designed to do biologically. Celldex reported rapid and profound suppression of circulating tryptase, the standard marker of systemic mast cell depletion, and said the regimen was well tolerated. Its conclusion was that mast cells may simply not be a central driver of symptoms in prurigo nodularis. Chief executive Anthony Marucci said it was disappointing that the study had not confirmed the promising signal seen in an earlier intravenous Phase 1b trial.

Understanding the Science

Mast cells are immune cells that sit in skin, gut and airway tissue and release histamine and other mediators when triggered. They depend on a receptor called KIT for survival. Barzolvolimab blocks KIT, which depletes mast cells rather than merely blunting one of their signals. That is a blunter and more complete intervention than blocking IgE or a single cytokine, and it explains both the drug's striking effects in hives and its characteristic side effects, which include reversible hair colour change, mild skin hypopigmentation and transient neutropenia.

The logic for testing it in prurigo nodularis was that mast cells cluster in the itchy nodules that define the disease. The trial tested that hypothesis directly: the cells were removed, and the itch stayed. That is a cleaner negative than a dosing failure, and it narrows where an anti-KIT antibody is likely to work. The same question now hangs over the ongoing Phase 2 in atopic dermatitis.

The Clinical and Regulatory Evidence

The case for barzolvolimab rests on chronic spontaneous urticaria, or CSU, the chronic hives condition where patients get welts and swelling for months or years with no identifiable trigger. In a 208-patient Phase 2 dose-finding study, mean change from baseline in the weekly urticaria activity score (UAS7) at week 12 was -23.87 for 300 mg every eight weeks and -23.02 for 150 mg every four weeks, against -10.47 on placebo, both with p-values below 0.0001. Complete disease control, meaning a UAS7 of zero, was reached by 51.1% of the 150 mg group and 37.5% of the 300 mg group, versus 6.4% on placebo.

More unusually, the effect persisted after dosing stopped. At week 76, seven months after the last dose, Celldex reported complete response in 41% and 35% of the two dose arms. Those are open-label, post-treatment observations rather than placebo-controlled findings, so they are suggestive rather than conclusive, but they are the basis for the company's argument that the drug may modify the disease rather than suppress it.

That evidence now goes to the test that matters. EMBARQ-CSU1 (NCT06445023, 963 patients) and EMBARQ-CSU2 (NCT06455202, 976 patients) enrolled 1,939 patients across 43 countries and more than 500 sites, finishing recruitment in February 2026, six months ahead of plan. Both compare 150 mg every four weeks and 300 mg every eight weeks against placebo, with UAS7 at week 12 as the primary endpoint and analysis triggered once every patient completes the 24-week placebo-controlled portion. Celldex reiterated in the 21 July release that topline data are expected in September or October 2026, with a BLA filing planned for 2027. Separate Phase 3 studies in cold urticaria and symptomatic dermographism are still enrolling.

The Commercial Opportunity

CSU is no longer an empty field. Omalizumab (Xolair) has been the standard biologic for antihistamine-refractory patients for a decade. Dupilumab (Dupixent) won FDA approval for CSU in April 2025. Novartis then secured approval for Rhapsido (remibrutinib) in late October 2025, the first oral targeted therapy for the disease: a meaningful competitive fact, because a pill is easier to prescribe and easier to start than an injected antibody. Jasper Therapeutics is developing briquilimab, another anti-KIT antibody, and reported updated Phase 1b/2a CSU data in January 2026.

Barzolvolimab's differentiation, if the Phase 3 data hold, would be depth and durability of response rather than novelty of target. Against that, it would enter a market where the incumbents are marketed by Genentech, Sanofi/Regeneron and Novartis, and where payers will have cheaper options to try first. Celldex has not disclosed pricing assumptions or launch plans.

Financial Position

Celldex reported cash, cash equivalents and marketable securities of $451.5 million at 31 March 2026, and closed a follow-on equity offering of 11.9 million shares for $345 million in gross proceeds in April. The first quarter net loss was $78.7 million, or $1.18 per share, against $53.8 million a year earlier, driven by research and development spending of $73.0 million versus $52.6 million. General and administrative costs were $11.4 million. Revenue is negligible, at $15,000 in the quarter. The company guided that its resources are sufficient to fund current planned operations through 2028. Shares outstanding were 66.6 million at quarter-end and roughly 78.5 million after the April raise.

That is comfortable for a company of this stage, but it is comfortable because Celldex sold equity after a run in the stock, not because the business generates cash. There is no marketed product and no partner revenue.

The Stock-Market Reaction

Calling this a sell-off would overstate it. The after-hours drop of as much as 10% on 21 July compressed to a 2.5% decline at Wednesday's close, and the stock recovered to $35.42 on 23 July and $35.28 on 24 July. Over twelve months the shares are up more than 50%.

Analyst reaction was similarly restrained. Canaccord Genuity trimmed its target from $62 to $60 while keeping a Buy rating, saying it had removed prurigo nodularis from its model and describing the valuation impact as limited. Published targets across covering firms span roughly $34 to $100. These are estimates, and the range reflects real disagreement about a binary event rather than consensus.

Key Growth Catalysts

  • EMBARQ-CSU1 and CSU2 topline data, guided by the company for September or October 2026.
  • Phase 2 atopic dermatitis topline, expected late 2026.
  • A BLA submission planned for 2027 if the CSU data support it.
  • Phase 3 readouts in cold urticaria and symptomatic dermographism; timing not disclosed.
  • CDX-622, a bispecific antibody against stem cell factor and TSLP; first-in-human Phase 1 data were presented in June 2026 showing dose-dependent, durable tryptase reductions, and a proof-of-mechanism study in mild-to-moderate asthma began in January 2026.

CDX-585, the PD-1 x ILT4 bispecific, was discontinued in November 2024 when Celldex refocused on inflammation, and is not part of the current pipeline.

Major Risks

The concentration risk is close to absolute. Barzolvolimab in urticaria is the company. A failure or an ambiguous result in EMBARQ would not be cushioned by the rest of the pipeline, which consists of one Phase 1 bispecific.

Phase 2 results in immunology frequently shrink in Phase 3, where placebo response rates tend to run higher in larger, more geographically dispersed populations. The prurigo nodularis placebo arm is a reminder of how much itch improves on nothing at all. The safety profile (hair depigmentation in around 9% of patients and neutropenia in around 8% in Phase 2) is manageable in trials but becomes a labelling and adherence question in a chronic, non-life-threatening disease where an oral alternative already exists.

Commercially, even clean data lead into a market with three approved competitors and a payer environment that will require step-through. The equity has also priced in a good deal of optimism after a strong twelve months, which raises the downside if the readout disappoints.

Conclusion

The prurigo nodularis failure removed an option, not the thesis, which is why the share price moved so little. What it did do was raise the stakes on the September-or-October readout by eliminating one of the ways barzolvolimab could have grown beyond hives, and by supplying a real example of mast cell depletion producing no clinical benefit.

Everything now turns on two Phase 3 trials whose results are weeks away. The Phase 2 evidence in CSU is strong, the balance sheet funds operations through 2028, and the competitive set is crowded but not settled. None of that constitutes proof of approval, and a company with one asset and one imminent binary event is a different proposition from a diversified biotech. Investors will need to form their own view on whether the current valuation already reflects a positive outcome.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.